We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+27.17%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.66B
AUM Growth
+$374M
Cap. Flow
+$115M
Cap. Flow %
6.95%
Top 10 Hldgs %
47.85%
Holding
212
New
55
Increased
41
Reduced
36
Closed
38

Top Buys

Rank Stock Value
1
RXDX
Ignyta, Inc.
RXDX
+$23.8M
2
VTRS icon
Viatris
VTRS
+$14.8M
3
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
+$14.4M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$12.4M
5
NVRO
NEVRO CORP.
NVRO
+$12.3M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$19.4M
2
BLUE
bluebird bio
BLUE
+$16.3M
3
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
+$12.1M
4
QURE icon
uniQure
QURE
+$11.1M
5
RLYP
RELYPSA INC COM
RLYP
+$10.8M

Sector Composition

Rank Sector Weight
1 Healthcare 81.96%
2 Consumer Staples 0.52%
3 Financials 0.09%
4 Technology 0.06%
5 Consumer Discretionary 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MGCD
101
DELISTED
MGC Diagnostics Corporation
MGCD
$1.76M 0.11%
336,287
– –
ARIA
102
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$1.59M 0.1%
191,949
+150,000
+358% +$1.33M
INCY icon
103
Incyte
INCY
$26.3B
$1.56M 0.09%
15,000
+5,000
+50% +$518K
SCYX icon
104
SCYNEXIS
SCYX
$51.6M
$1.54M 0.09%
+2,188
New +$1.57M
SAGE
105
DELISTED
Sage Therapeutics
SAGE
$1.46M 0.09%
20,000
-50,484
-72% -$3.25M
BCLI
106
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
$1.44M 0.09%
26,667
– –
EPZM
107
DELISTED
Epizyme, Inc
EPZM
$1.44M 0.09%
+60,000
New +$1.15M
AVGR
108
DELISTED
Avinger, Inc. Common Stock
AVGR
$1.32M 0.08%
1
– –
TCON
109
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$1.29M 0.08%
500
– –
AET
110
DELISTED
Aetna Inc
AET
$1.29M 0.08%
10,086
+7,500
+290% +$856K
GNVC
111
DELISTED
GenVec, Inc.
GNVC
$1.26M 0.08%
61,584
– –
EYPT icon
112
EyePoint Inc
EYPT
$431M
$1.19M 0.07%
31,500
– –
CGNT
113
DELISTED
Cogentix Medical, Inc.
CGNT
$1.09M 0.07%
+673,257
New +$1.1M
LKFT
114
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.94B
$1.03M 0.06%
+20,000
New +$1.06M
IMPR
115
DELISTED
IMPRIVATA, INC COM
IMPR
$982K 0.06%
60,000
+10,000
+20% +$150K
STML
116
DELISTED
Stemline Therapeutics, Inc.
STML
$933K 0.06%
79,245
– –
NGNE icon
117
Neurogene
NGNE
$817M
$902K 0.05%
6,500
– –
STLA icon
118
Stellantis
STLA
$19.8B
$901K 0.05%
+95,090
New +$975K
DHR icon
119
Danaher
DHR
$152B
$856K 0.05%
+14,878
New +$852K
GLMD icon
120
Galmed Pharmaceuticals
GLMD
$4.48M
$755K 0.05%
52
– –
GRCE
121
Grace Therapeutics
GRCE
$46.3M
$745K 0.04%
4,928
– –
DRNA
122
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$698K 0.04%
+50,000
New +$917K
ABMD
123
DELISTED
Abiomed Inc
ABMD
$657K 0.04%
10,000
– –
TRIL
124
DELISTED
Trillium Therapeutics Inc.
TRIL
$655K 0.04%
+30,000
New +$684K
HSTO
125
DELISTED
Histogen Inc. Common Stock
HSTO
$515K 0.03%
+500
New +$586K
3 4
5
6 7

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return
MCM
Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return

Perceptive Advisors's Q2 2015 Portfolio in Review

As of Q2 2015, Perceptive Advisors held 212 positions worth $1.66B, up 29% from $1.29B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Perceptive Advisors deployed $115M of net new capital in Q2 2015, opening 55 new positions and adding to 41 existing holdings. Its largest new stake was Ignyta, Inc.: 1,967,600 shares worth $29.7M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 84% a quarter earlier, followed by Consumer Staples and Financials.

On the sell side, the largest reduction was Neurocrine Biosciences, an estimated $19.4M trimmed.

  • Perceptive Advisors's largest Q2 2015 buy was Ignyta, Inc.: 1,967,600 shares worth $29.7M.
  • Perceptive Advisors added most to Viatris in Q2 2015, an estimated $14.8M increase.
  • Perceptive Advisors's biggest Q2 2015 reduction was Neurocrine Biosciences, cutting an estimated $19.4M.
  • Perceptive Advisors fully exited bluebird bio in Q2 2015, selling an estimated $16.3M.
  • Perceptive Advisors's ten largest holdings make up 48% of its $1.66B portfolio in Q2 2015.
  • Perceptive Advisors opened 55 new positions and closed 38 in Q2 2015.
  • Perceptive Advisors's portfolio value rose 29% quarter-over-quarter to $1.66B.

Based on Perceptive Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.